April 28 - May 1 | Palma de Mallorca, ES
April 28 - May 1 | Palma de Mallorca, ES
April 28 - May 1 | Palma de Mallorca, ES
April 28 - May 1 | Palma de Mallorca, ES
April 28 - May 1 | Palma de Mallorca, ES
My experience submitting a scientific abstract
Why did you choose ECIO to submit your scientific abstract?
I selected ECIO due to my research focus on transarterial chemoembolization treatment for hepatocellular carcinoma, a topic frequently discussed and presented in past ECIO conferences.
Tell us a little bit about your research and the results you submitted.
I wrote an abstract about a study protocol for a clinical study. In this study, patients undergoing transarterial chemoembolization are administered two doses of Idarubicin. A PET/MRI is conducted both before and after the first TACE.
Biopsies are also taken for multi-omics analyses, organoid growth, and histology. I chose to present it because it is the most recent research from our group.
Are there any special considerations to take into account when submitting a scientific abstract?
Submit an abstract following IMRAD format and read the instructions from the conference website thoroughly. Avoid repetition, use simple language and specify objectives.
Will you submit another abstract for ECIO 2024?
No, not for ECIO 2024, as our clinical trial is still ongoing, and there is not enough data to present yet. Maybe I will send you an abstract in 2025.
Why did you choose ECIO to submit your scientific abstract?
The DRAGON collaborative investigates a novel and promising procedure called PVE/HVE. This procedure aims to increase the future liver remnant (FLR) of patients with primary or secondary liver cancer with a FLR that is too small for resection. The hypothesis is that, by performing this procedure, we can safely increase the resectability in these patients which might lead to improved oncological outcomes. The combination of a new procedure performed by IR with oncology seemed to be a perfect match for ECIO.
Tell us a little bit your research and the data you submitted.
The dragon trial collaborative is a group of centres (>50 wordlwide) with the aim to improve treatment options for patients with primary or secondary liver cancers. Over the past years, we have been investigating PVE/HVE. In the first trial, the DRAGON 0, we retrospectively collected the first PVE/HVE cases within the DRAGON centres and compared the effectiveness of PVE/HVE with PVE cases of the same centres in the same years. We showed an increased FLR volume growth and a higher resectability rate. Now, 3 years later, we presented the 3-year oncological follow-up of these patients.
Are there any special considerations to take into account when submitting a scientific abstract?
For me personally, there aren’t. For this study/research, ECIO is the right stage and submitting via the portal was very clear and easy. In case I had a question, communication was also accessible and clear.
Do you have any tips for physicians submitting an abstract for the first time?
Do not hesitate, the congress and its program are excellent and everything is very well organised.
Will you submit another abstract for ECIO 2024?
Our DRAGON team will definitely make another submission.